POS1365 ANNALYSIS OF PRO-INFLAMMATORY BIOMARKERS IN A POLYMYALGIA RHEUMATICA COHORT DURING THE ACUTE ONSET OF THE DISEASE

Background: Polymyalgia Rheumatica (PMR) is a common inflammatory disease found in elderly patients and results high burden of long-term CS-based therapies. Most diagnosed with PMR have good evolution following the introduction medium-dose glucocorticoid treatment. However, need to maintain corticosteroid treatment for an extended period (around 12-15 months) often norm standard clinical practice. Activation Th-17 lymphocytes consequent action pro-inflammatory cytokines such as IL-1, IL-6, IL-17, or IL-23 well known acute phase this treated by glucocorticoids IL-6 blockers satisfactorily. activation Th-1 appears play leading role chronic through INF-gamma IL-12. Objectives: Our aim was assess proinflammatory biomarkers cohort during onset its possibly relationship dose. Methods: Prospective study wide unselected series classified 2012 ACR/EULAR classification criteria PMR. Patient evaluations were performed at baseline 3 6 months after initiation therapy. Serum levels interleukin-6 (IL-6), interleukin-8 (IL-8), CXC motif ligand 10 chemokine (CXCL10), 9 (CXCL9), 2 (CXCL2) CC (CCL2) measured healthy controls. Results: A total 25 studied (32% men; 68% women). The mean age 72.72 ±9.32 years (range 65-79). We also included 35 In reference laboratory parameters PMR, values (± deviation) follows: C reactive protein (CRP): 28.4±26.6 mg/dL; erythrocyte sedimentation rate (ESR): 54.3±21.3 mm/h; haemoglobin: 12.6±1.6 g/dL; IL-6: 17.6±30.1 pg/mL; IL-8: 10.1±6.9 CXCL10: 259.4±290.7 CXCL9:5175±4396.8 pg/mL;, CXCL2: 25.9±12.5 CCL2: 471.3±152.9 pg/mL. IL-8 CXCL9 significantly increased comparing control group. Health Assessment Questionnaire (HAQ) yielded value 1.6±0.6. dose prednisone employed 14.8±5.6 mg/day. After months, 6.7±3.9 mg/day, median [range] CRP 3.1 [1.75-7.2] mg/dl ESR 22±14 mm/h. Regarding between doses employed, no differences observed. pain perception disability, we observed higher visual analogic scale (VAS) association (P=0.03) HAQ CXCL2 values. our showed excellent evolution, complications Conclusion: During population patients. No employed. Disclosure Interests: None declared